Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 105 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Katsiki, Niki [Clear All Filters]
Fibrinogen, hematocrit, and platelets in mild kidney dysfunction and the role of uric acid: an Italian male population study..
Clin Appl Thromb Hemost. 18(1), 113-4.
(2012). Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome..
Expert Opin Pharmacother. 13(2), 287-8; author reply 289-90.
(2012). Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity..
Am J Cardiol. 110(5), 763.
(2012). Response to 'Mildly decreased glomerular filtration rate is associated with poor coronary heart disease outcome'..
Clin Cardiol. 35(5), 315; author reply 316-7.
(2012). Should raising high-density lipoprotein cholesterol be a matter of debate?.
J Cardiovasc Med (Hagerstown). 13(4), 254-9.
(2012). Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial..
J Hepatol. 57(2), 476.
(2012). Stage of chronic kidney disease and severity of coronary heart disease manifestation..
Expert Opin Pharmacother. 13(4), 457-60.
(2012).
(2012). 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?.
Metabolism. 62(1), 21-33.
(2013). Alcohol consumption and the heart..
Int J Cardiol. 168(4), 4319.
(2013). Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients..
Curr Med Res Opin. 29(7), 791-2.
(2013). Cold temperature and cardiovascular mortality..
Circ J. 77(11), 2846.
(2013). Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease..
Expert Opin Ther Targets. 17(7), 861-2.
(2013). Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property"..
Dig Liver Dis. 45(1), 82-3.
(2013). Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review..
Curr Med Res Opin. 29(10), 1263-74.
(2013). The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study..
Curr Vasc Pharmacol. 11(5), 779-84.
(2013). Metabolic syndrome and arterial stiffness: the past, the present and the future..
J Cardiovasc Med (Hagerstown). 14(10), 687-9.
(2013). Nonalcoholic fatty liver disease and severity of cardiovascular disease manifestations..
Angiology. 64(8), 572-5.
(2013). Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention..
Circ J. 77(5), 1348.
(2013). Statins and nonalcoholic fatty liver disease: a bright future?.
Expert Opin Investig Drugs. 22(9), 1089-93.
(2013). The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!.
Curr Med Res Opin. 30(9), 1701-5.
(2014). Achieving lipid targets in primary care settings..
Curr Med Res Opin. 30(10), 1971-4.
(2014).
(2014). Are statins 'IDEAL' for non-alcoholic fatty liver disease?.
Curr Med Res Opin. 30(2), 229-31.
(2014). Beneficial effects of high atorvastatin dose reloading prior to percutaneous coronary intervention..
Curr Med Res Opin. 30(1), 55.
(2014).